This is again a study based on patients with aromatase receptor-positive breast cancer, but in this case it is metastatic breast cancer. We studied how the physicians and oncologists were thinking about the possibility of switching CDK4/6 from one to another only when there was a toxicity that was inaccessible. So the importance of this study is the physician was very proud about the FDA indication because you can use the first-line treatment for a long time and you have not to stop based on the adverse events...
This is again a study based on patients with aromatase receptor-positive breast cancer, but in this case it is metastatic breast cancer. We studied how the physicians and oncologists were thinking about the possibility of switching CDK4/6 from one to another only when there was a toxicity that was inaccessible. So the importance of this study is the physician was very proud about the FDA indication because you can use the first-line treatment for a long time and you have not to stop based on the adverse events. So this is another important point for the oncologist at this moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
